Factors associated with dose adjustment for the bortezomib, lenalidomide, dexamethasone regimen among patients with newly diagnosed multiple myeloma.

被引：0
|
作者：
Ran, Tao
Medhekar, Rohan
Fu, Alex Z.
Patel, Sharmila
Kaila, Shuchita
机构：
[1] Janssen Sci Affairs LLC, Horsham, PA USA
[2] Georgetown Univ, Med Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8039
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Predictors of response to upfront bortezomib, lenalidomide and dexamethasone (VRd) in multiple myeloma.
    Keruakous, Amany
    Day, Silas
    Borogovac, Azra
    Holter, Jennifer L.
    Asch, Adam Steven
    Yuen, Carrie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review
    McCaughan, Georgia J.
    Gandolfi, Sara
    Moore, John J.
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 190 - 204
  • [23] Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone
    Loncharich, Alexa J.
    Fiala, Mark A.
    Slade, Michael J.
    Vickroy, Angela
    Kavanaugh, Margaret
    Wilson, Carmen
    Schroeder, Mark A.
    Stockerl-Goldstein, Keith
    Vij, Ravi
    Sanfilippo, Kristen M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (11): : 825 - 828
  • [24] Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Kaufman, Jonathan L.
    Mina, Roberto
    Shah, Jatin J.
    Laubach, Jacob P.
    Nooka, Ajay K.
    Lewis, Colleen
    Gleason, Charise
    Sharp, Cathy
    Harvey, R. Donald
    Heffner, Leonard T.
    Richardson, Paul
    Lonial, Sagar
    Orlowski, Robert Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (12): : 797 - 803
  • [25] Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
    O'Gorman, Peter
    Laubach, Jacob P.
    O'Dwyer, Michael E.
    Krawczyk, Janusz
    Yee, Andrew J.
    Gilligan, Oonagh
    Cahill, Mary R.
    Rosenblatt, Jacalyn
    Quinn, John
    Murphy, Philip T.
    DiPietro, Heidi
    Perera, Meegahage Ratnakanthi
    Crotty, Gerard M.
    Cummings, Kristen
    Hayden, Patrick J.
    Browne, Paul
    Savell, Alexandra
    O'Leary, Hilary M.
    O'Keeffe, Denis
    Masone, Kelly
    Hennessy, Brian J.
    Garcia, Thomas Guerrero
    Scott, Kathleen
    Saeed, Khalid
    Bianchi, Giada
    Dowling, Paul
    Tierney, Ciara
    Richardson, Paul G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (05) : 562 - 573
  • [26] Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone
    Loncharich, Alexa J.
    Fiala, Mark A.
    Slade, Michael J.
    Vickroy, Angela
    Kavanaugh, Margaret
    Wilson, Kari
    Schroeder, Mark A.
    Stockerl-Goldstein, Keith E.
    Vij, Ravi
    Sanfilippo, Kristen M.
    BLOOD, 2022, 140 : 8550 - 8551
  • [27] Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients
    Joseph, Nisha
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Gleason, Charise
    Heffner, Leonard
    Boise, Lawrence H.
    Kaufman, Jonathan L.
    Dhodapkar, Madhav V.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD, 2018, 132
  • [28] Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
    Laubach, Jacob P.
    Schlossman, Robert L.
    Mitsiades, Constantine S.
    Anderson, Kenneth C.
    Richardson, Paul G.
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (01) : 51 - 60
  • [29] Alternating bortezomib-dexamethasone and lenalidomide- dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
    Yokoyama, Akihiro
    Kada, Akiko
    Kagoo, Toshiya
    Hidake, Michihiro
    Iida, Hiroatsu
    Miyata, Yasuhiko
    Saito, Akiko M.
    Sawamura, Morio
    Komeno, Takuya
    Sunami, Kazutaka
    Takezako, Naoki
    Nagai, Hirokazu
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2022, 84 (01): : 80 - 90
  • [30] Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
    Oriol, Albert
    Dimopoulos, Meletios
    Schjesvold, Fredrik
    Beksac, Meral
    Facon, Thierry
    Dhanasiri, Sujith
    Guo, Shien
    Mu, Yutian
    Hong, Kevin
    Gentili, Christian
    Galli, Monica
    Yagci, Munci
    Larocca, Alessandra
    Richardson, Paul
    Weisel, Katja
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : 165 - 176.e4
12345